Results 41 to 50 of about 14,917 (240)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Experimental Hematology & Oncology, 2023
Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R)
Xubo Gong, Yi Zhang, Xin He, Milad Moloudizargari, Teng Yu, Lin Wang, Weiwei Liu, Lan Jin, Huiying Xu, Yang Xu, Zhihua Tao, Wenbin Qian   +11 more
doaj   +1 more source

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma [PDF]

, 2016
Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes.
Azab, M., Cannito, S., CAPPELLO, Francesco, Jueliger, S., Lo Re, O., Lyons, J., Pata, I., Pata, P., Pazienza, V., Peyrou, M., RAPPA, Francesca, Shkolnaya, M., Taverna, P., Villarroya, F., Vinciguerra, M.   +14 more
core   +2 more sources

Effect of the reverse transcriptase inhibitor efavirenz on 5-azacytidine-induced LINE1 long interspersed repeat expression and genetic instability in acute myeloid leukemia cells

Успехи молекулярной онкологии
Introduction. The use of hypomethylating agents in the treatment of acute myeloid leukemia has increased overall patient survival by 12 %. However, alongside their potent antitumor effect, hypomethylating agents negatively impact genome stability due to ...
Kh. M. Magomedova, I. A. Antonova, M. S. Strelkov, V. A. Nurtdinova, V. T. Cheshchevik, K. I. Kirsanov, G. A. Belitsky, M. G. Yakubovskaya, O. A. Vlasova   +8 more
doaj   +1 more source

Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study [PDF]

, 2012
INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML.
Berdel, Wolfgang E., Brandts, Christian Hubertus, Bug, Gesine, Büchner, Thomas, Dührsen, Ulrich, Ehninger, Gerhard, Gerss, Joachim, Koschmieder, Anja, Koschmieder, Steffen, Krug, Utz, Müller-Tidow, Carsten, Noppeney, Richard, Röllig, Christoph, Schaich, Markus, Schwammbach, Daniela, Serve, Hubert, Steffen, Björn, Stelljes, Matthias, Thiede, Christian, Tidow, Nicola   +19 more
core   +3 more sources

Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong

Therapeutic Advances in Hematology
Background: The pivotal trial on venetoclax and hypomethylating agents in unfit elderly acute myeloid leukaemia (AML) has got FDA approval. However, Asian patients were under-represented and showed no survival advantage.
Qiwen Fang, Chi Yeung Fung, Jiaqi Wang, Wing Hei Lai, Raymond S. M. Wong, Bonnie C. S. Kho, June S. M. Lau, Vivien W. M. Mak, Chung Yin Ha, Xue Li, Anskar Yu-Hung Leung   +10 more
doaj   +1 more source

Dasatinib and azacitidine followed by haploidentical stem cell transplant for chronic myeloid leukemia with evolving myelodysplasia: A case report and review of treatment options. [PDF]

, 2017
BACKGROUND: CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, additional chromosomal aberrations, and evolving MDS is uncommon and therapeutically challenging.
Ottmann, Oliver
core   +2 more sources

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

Epigenetics in diagnosis, prognostic assessment and treatment of cancer:An update [PDF]

, 2014
Cancer cells contain multiple genetic and epigenetic changes. The relative specificity of many epigenetic changes for neoplastic cells has allowed the identification of diagnostic, prognostic and predictive biomarkers for a number of solid tumors and ...
Briasoulis, Evangelos, Crook, Tim, Hatzimichael, Eleftheria, Lagos, Konstantinos, Sim, Van Ren   +4 more
core   +4 more sources

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes [PDF]

Current Opinion in Hematology, 2014
Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1-2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure of HMA therapy is associated with a very dismal prognosis.
Amer M, Zeidan, Mohamed A, Kharfan-Dabaja, Rami S, Komrokji   +2 more
openaire   +2 more sources